Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure.
Saved in:
| Title: | Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure. |
|---|---|
| Authors: | Vogler S; WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Department of Pharmacoeconomics, Austrian National Public Health Institute (Gesundheit Österreich GmbH/GÖG), Vienna, Austria., Schneider P; WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Department of Pharmacoeconomics, Austrian National Public Health Institute (Gesundheit Österreich GmbH/GÖG), Vienna, Austria., Zuba M; Department of Health Economics and Health Systems Analysis, Austrian National Public Health Institute (Gesundheit Österreich GmbH/GÖG), Vienna, Austria., Busse R; Department of Health Care Management, Technische Universität Berlin, Berlin, Germany., Panteli D; Department of Health Care Management, Technische Universität Berlin, Berlin, Germany. |
| Source: | Frontiers in pharmacology [Front Pharmacol] 2021 Jun 25; Vol. 12, pp. 625296. Date of Electronic Publication: 2021 Jun 25 (Print Publication: 2021). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1663-9812 |
|---|---|
| DOI: | 10.3389/fphar.2021.625296 |
